CN111491923A - N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 - Google Patents

N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 Download PDF

Info

Publication number
CN111491923A
CN111491923A CN201880081567.2A CN201880081567A CN111491923A CN 111491923 A CN111491923 A CN 111491923A CN 201880081567 A CN201880081567 A CN 201880081567A CN 111491923 A CN111491923 A CN 111491923A
Authority
CN
China
Prior art keywords
ring
compound
pharmaceutically acceptable
acceptable salt
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880081567.2A
Other languages
English (en)
Other versions
CN111491923B (zh
Inventor
周福生
蒋涛
王海龙
刘力锋
陈曦
奚悦
刘伟
李进
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN111491923A publication Critical patent/CN111491923A/zh
Application granted granted Critical
Publication of CN111491923B publication Critical patent/CN111491923B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

涉及N‑(2‑环己基乙基)甲酰胺衍生物、其制法与医药上的用途。具体地，本发明公开了式(I)化合物或其药学上可接受的盐、立体异构体或溶剂化合物，及其制备方法和应用。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201880081567.2A 2017-12-22 2018-12-21 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 Active CN111491923B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711415856.5A CN109956937A (zh) 2017-12-22 2017-12-22 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途
CN2017114158565 2017-12-22
PCT/CN2018/122819 WO2019120298A1 (zh) 2017-12-22 2018-12-21 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途

Publications (2)

Publication Number Publication Date
CN111491923A true CN111491923A (zh) 2020-08-04
CN111491923B CN111491923B (zh) 2023-06-16

Family

ID=66994441

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711415856.5A Pending CN109956937A (zh) 2017-12-22 2017-12-22 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途
CN201880081567.2A Active CN111491923B (zh) 2017-12-22 2018-12-21 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201711415856.5A Pending CN109956937A (zh) 2017-12-22 2017-12-22 N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途

Country Status (2)

Country Link
CN (2) CN109956937A (zh)
WO (1) WO2019120298A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂
WO2017192844A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192840A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516681A (ja) * 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
WO2017192844A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192840A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

Also Published As

Publication number Publication date
CN109956937A (zh) 2019-07-02
WO2019120298A1 (zh) 2019-06-27
CN111491923B (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
JP7085566B2 (ja) アポトーシス誘発剤
RU2717577C2 (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP5579704B2 (ja) フェニルおよびベンゾジオキシニル置換インダゾール誘導体
JP2019513743A (ja) インドールアミン ２，３−ジオキシゲナーゼ阻害剤、その製造方法及び応用
CA2802216C (en) Tetrahydrocarboline derivative and its use as an enpp2 inhibitor
CA2901022A1 (en) Substituted pyridine compounds as inhibitors of histone demethylases
WO2016197987A1 (zh) 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2021052501A1 (zh) 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN102134234B (zh) 吲唑脲类化合物及其制法和药物用途
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN111491923A (zh) N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途
WO2016088834A1 (ja) ジヒドロナフタレン誘導体
JP2020519569A (ja) ベンゾフラン誘導体遊離塩基の結晶およびその製造方法
JP7152078B2 (ja) ホウ酸塩ベースの薬物およびその使用
WO2003051838A2 (en) Protein kinase inhibitors
WO2020173417A1 (zh) 含丙烯酰基的核转运调节剂及其用途
WO2019091046A1 (zh) 一种来那度胺的衍生物的制备方法与应用
JP2024509243A (ja) 複素環置換ケトン類誘導体、その組成物および医薬における使用
CN107793360B (zh) 吲哚胺2,3-双加氧酶抑制剂与应用
JP2021531302A (ja) アゼチジン誘導体のボレート
TW202035406A (zh) 作為cdk-hdac雙通路抑制劑的雜環化合物
WO2019184919A1 (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
CN110105275B (zh) 酰胺类衍生物、其制法与医药上的用途
CN112384502B (zh) 环烷基取代的酰胺类衍生物、其制法与医药上的用途
JPWO2017183723A1 (ja) Ｋｃｎｑ２〜５チャネル活性化剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant